ABSTRACT
Density maps show trends in objects' trajectories. Density map creation involves aggregating smoothed trajectories in a density field and visualizing the field. Using an interactive distribution map, users can define subsets and, supported by graphics hardware, get fast feedback for these computationally expensive density field calculations.
ABSTRACT
BACKGROUND: Time between symptom onset and effective reperfusion is of paramount importance in patients with acute myocardial infarction (MI) treated with reperfusion therapy. In the PHIAT (Pre-Hospital Infarction Angioplasty Triage) project, safety and feasibility of in-ambulance electrocardiography facilities for prehospital triage for direct transfer to an interventional centre to undergo immediate coronary angiography and angiography-guided therapy were evaluated. METHODS AND RESULTS: The ambulances were equipped with a defibrillator and electrocardiography unit with computerised electrocardiographic analysis. Patients with acute MI symptoms and fulfilling certain criteria compatible with a large MI were included and pretreated with heparin and aspirin during transportation. During the study period, 284 patients were included. Eleven percent did not have an acute MI. PCI, performed in 94% (n=239) of the patients, was successful in 94%. Prehospital triage reduced time to treatment. In 32% of the patients triage resulted in direct transportation to the interventional centre instead of to the nearest community hospital. All-cause mortality was 9% after a mean follow-up of nine months. No serious bleeding complications were seen. CONCLUSION: Prehospital triage in the ambulance is safe and feasible. A striking percentage (11%) of the identified patients does not have an acute MI and this is more than has been reported from prehospital thrombolysis trials.
ABSTRACT
A previously described method for the confirmatory analysis of clenbuterol with chemical ionization GC-MS was extended to fit more beta-agonists. The method has been used routinely for about one year and a large number of samples have been analysed according to the described procedure. This paper summarizes the results obtained with this method with regard to clenbuterol and furthermore discussion is focused on applicability to beta-agonists other than clenbuterol with respect to the European Community requirements for confirmatory analysis.
